Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Applied BioCodeTPE:6598 -1.40%75 3-1 Month Momentum % is 24.38% as of Sep. 02, 2026. GuruFocus rates TPE:6598 with a GF Score™ of 75/100 and a GF Value™ of NT$31.95 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Applied BioCode ranks better than 92.83% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-02), Applied BioCode's 3-1 Month Momentum % is 24.38%.
The industry rank for Applied BioCode's 3-1 Month Momentum % or its related term are showing as below:
TPE:6598's 3-1 Month Momentum % is ranked better than 92.83% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: -5.34
vs TPE:6598: 24.38
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Applied BioCode 3-1 Month Momentum % Related Terms
TPE:6598 vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Applied BioCode's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Applied BioCode's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied BioCode (TPE:6598) has a 3-1 Month Momentum % of 24.38% as of Sep. 02, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Applied BioCode and its competitors. According to the industry distribution chart, Applied BioCode ranks #61 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 7.2%.
Is Applied BioCode's 3-1 Month Momentum % too high?
Applied BioCode's current 3-1 Month Momentum % is 24.38%. Based on the distribution chart, Applied BioCode ranks #61 out of 851 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Applied BioCode has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #61 out of 851 companies for 3-1 Month Momentum %. This places Applied BioCode in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Applied BioCode and its competitors. Applied BioCode's current 3-1 Month Momentum % is 24.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$31.95, compared to a current price of NT$28.15 — trading 11.9% below its estimated fair value. The current 3-1 Month Momentum % is 24.38%. Applied BioCode's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current 3-1 Month Momentum % is 24.38% as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued.
The current stock price of NT$28.15 is trading 11.9% below its estimated GF Value™ of NT$31.95.
GuruFocus considers Applied BioCode to be Modestly Undervalued.
Key valuation signals for TPE:6598:
3-1 Month Momentum %: 24.38%
GF Value™: NT$31.95 vs. price of NT$28.15 (11.9% below fair value)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
75GF Score
Get the complete analysis for TPE:6598
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
